The excitatory amino antagonist MK-80 1 was administered to cats following resuscitation from cardiac arrest to evaluate its effect on neurologic and neuropatho logic outcome in a clinically relevant model of complete cerebral ischemia. In 29 cats studied, cardiac arrest (ven tricular fibrillation) was maintained for 18 min and resus citation was successfully performed in 21 cats. Four an imals underwent a sham arrest. MK-80 1 or placebo was administered in a blinded, randomized manner. Beginning at 5 min post resuscitation (PR), MK-80 1 330 lLg/kg over 2 min fo llowed by 73 lLg/kg/h for 10 h or the same volume of placebo was administered. Resuscitated animals re mained paralyzed and sedated in an intensive care setting for 24--30 h PRo Neurologic examinations were performed at 2, 4, and 7 days PR by observers blinded to the treat ment groups. Seventeen cats were entered into data anal ysis (nine MK-80 1-treated and eight placebo-treated).
MK-801-treated animals had a significantly greater neu rologic deficit score (NDS) rank (0 = normal, 100 = brain death) 2 days PR (mean rank 12.1 vS. 5.6; p = 0.008). This difference is most likely due to ongoing sed ative actions of MK-801. There were no significant dif fe rences in NDS rank at 4 (10.3, MK-80 1 vS. 7.5, placebo) and 7 (9.6, MK-80 1 vS. 8.3, placebo) days PRo There were no significant differences in frontal cortex, hippocampus, occipital cortex, or cerebellar neuropathology between groups. Sham-arrested cats had normal neurologic and neuropathologic evaluations. In the circumstance of com plete cerebral ischemia as employed in the current study, MK-80 1 had no beneficial effect upon neurologic or neu ropathologic outcome. Key Words: Cardiac arrest Cerebral ischemia-Cerebral protection-Excitatory amino acid antagonist, MK-801-N-Methyl-D-aspartate. different conductance states (Jahr and Stevens, 1987 ). These subtypes have been classified accord ing to the exogenous agonists that preferentially ac tivate them: N-methyl-D-aspartate (NMDA), quis qualate, and kainate. Glutamate is an effective ag onist for all three receptor subtypes. Excitatory amino acids (EAAs) such as glutamate are pre sumed to cause neuronal injury as a result of per sistent depolarization causing the normal cationic channels to be held in the "open" position with a resultant intracellular accumulation of cations (in cluding calcium) (M acDermott et aI., 1986; Roth man and Olney, 1986) . Several different avenues of investigation support a pathogenetic role for gluta mate in cerebral ischemia: (a) Areas of the brain that are most vulnerable to ischemia (hippocampus, cerebral cortex, striatum, and cerebellum) (Siesj6, 1984) receive significant glutamatergic inputs (Fagg and Foster, 1983) ; (b) prior lesioning of these glu tamatergic pathways prevents ischemia-induced neuronal damage in the hippocampus (Wieloch et aI. , 1985; Onodera et aI., 1986) ; (c) transient com plete cerebral ischemia in the rat is associated with an increase in glutamate concentration in the extra cellular space of the hippocampus (Benveniste et aI. , 1984) ; and (d) local microinjection of an NMDA antagonist (2-amino-7-phosphonoheptanoic acid) prior to insult protects against the hippocampal neu ronal damage caused by forebrain ischemia in the rat (Simon et aI., 1984; Swan et aI., 1988) .
MK-801 {( + )-5-methyl-1O, II-dihydro-5H-dibenzo [a,d] cyclohepten-5, 10-imine maleate}, a potent, noncompetitive NMDA receptor antagonist, is an orally active anticonvulsant (Clineschmidt et aI. , 1982) that readily crosses the blood-brain barrier (Hucker et aI. , 1983) . A series of recent investiga tions have examined the effects of MK-801 upon neuropathology and/or neurologic outcome follow ing experimental focal or forebrain ischemia in ger bils (Gill et aI. , 1987; Lawrence et aI. , 1987) , rats (Church et aI. , 1988; Park et aI. , 1988a) , cats (Ozyurt et aI., 1988; Park et aI. , 1988b) , and rabbits (Kochhar et aI. , 1988) . Significant neuronal protec tive effects of MK-801 have been demonstrated in each of these studies. As yet, no full report of the use of MK-801 with complete global cerebral isch emia is available.
The current study was designed to determine if MK-801 has protective effects on neurologic out come in a clinically relevant model of complete global cerebral ischemia [ventricular fibrillation (V F) in cats].
METHODS

Surgical preparation
With institutional review board approval, 29 colony bred (University of California, Davis, CA, U.S.A.) cats, aged 4-6 months and weighing 1.9-2.8 kg, were studied. They received only water ad libitum for 16-20 h prior to study. Animals were anesthetized with 4% halothane in Oz delivered into a Plexiglas box. Peripheral venous can nulas were placed in both forelegs, and pancuronium 0.3 mg/kg was injected intravenously to fa cilitate endotra cheal intubation with a 4.0-mm internal diameter cuffed endotracheal tube. Inspired halothane was decreased to 1.0-1.5% in 70% NzO and Oz. In the supine position, the cats were mechanically ventilated with a tidal volume of 15 mllkg, 5 cm HzO positive end-expiratory pressure (PEEP), and respiratory rate adjusted to maintain normo carbia (PaCOZ = 30-35 mm Hg). Esophageal temperature (servo-controlled to 37SC with a heating pad and lamp), ECG (lead 11), end-tidal concentration of COz (Accucap Oz/COz Monitor; Datascope, Paramus, NJ, U.S.A.), and halothane (Anesthetic Agent Monitor 22; Puritan-Bennet, Wilmington, MA, U.S.A.) were continuously monitored. The EEG was recorded from fr ontooccipital (Fz-Oz) and biparietal (C3-C4) leads, at a gain of 50 fL V /7 mm, with J Cereb Blood Flow Metab, Vol. 9, No.6, 1989 filter settings for low and high frequency at 1 and 30 Hz, respectively (model 78; Grass, Quincy, MA, U.S.A.). Animals received an infusion of normal saline at 4 mllkg/h and pancuronium at 0.2 mg/kg/h. After skin infiltration with 1 ml of 0.25% bupivacaine, cannulas were inserted using aseptic technique into the distal abdominal aorta and the right atrium (RA) via the left fe moral artery and vein, respectively. A wire (0.025 in in diameter) was inserted with its tip protruding 5 mm beyond the distal end of the RA cannula and the position was confirmed by ECG. The MABP, RA pressure (RAP) (both referenced to the level of RA), ECG, and EEG were continuously recorded on a polygraph recorder (model 2758; Hewlett-Packard, Waltham, MA, U.S.A.). After closure of the groin wound, inspired halothane was de creased to 0.5%, and the animal was left undisturbed for 30 min.
Cardiac arrest and resuscitation
Cardiac arrest and resuscitation were performed as pre viously described by Todd et al. (1982) with minor modi fications. After the 30-min postpreparation equilibration period, arterial blood gases, pH (IL-813; Instrumentation Laboratory, Lexington, MA, U.S.A.), plasma glucose (Glucose Analyzer 23A; YSI, Yellow Springs, OH, U.S.A.), hematocrit, and plasma electrolytes (Na/K Ion Analyzer; Nova Biomedical, Waltham, MA, U.S.A.) were measured. MABP, RAP, and heart rate were re corded and halothane was discontinued. One minute after discontinuation of halothane, VF was induced by passing a 20-V, 60-Hz alternating current between the RA wire and the subcutaneous precordial needle. Ventilation was simultaneously discontinued and the endotracheal tube was occluded. The fibrillating voltage was tapered to zero during the first minute of the arrest period. However, if spontaneous defibrillation occurred during this period, the voltage was increased to 20 V and the tapering re peated over an additional minute. After 4 min of VF, the RA wire and subcutaneous needle were removed. At 17.5 min, mechanical ventilation was resumed with 100% Oz at a respiratory rate 50% above the prearrest level. At 18 min after the induction of VF [time 0 post resuscitation (PR)], cardiopulmonary resuscitation (CPR) was initi ated. The thorax was compressed between the lateral walls of the rib cage at a rate of 100-120 compressions/ min. Efforts were made to maintain systolic pressure greater than 100 mm Hg and diastolic pressure greater than 50 mm Hg. Sodium bicarbonate 1.0 mEq/kg, epi nephrine 15 fLg/kg, and lidocaine 1.0 mg/kg were injected via the RA cannula simultaneously with the initiation of CPR. The same doses of these drugs were again admin istered after 1 min of CPR. After 2 min, a 25-J direct current (DC) shock was given between two chest paddles (DC defibrillator 640; Physiocontrol, Redmond, WA, U.S.A.) placed on the shaved lateral chest walls. Every 60 s, a 25-Joule DC shock and sodium bicarbonate, epi nephrine, and lidocaine in the same doses as above were repeated until defibrillation occurred (to a maximum of three shocks). All animals received atropine 25 fLg/kg at T = 3 min PR or after restoration of a spontaneous heart beat.
PR treatment
Resuscitation was considered successful if the systolic blood pressure was maintained above 100 mm Hg without CPR by T = 4 min PRo Following successful resuscita-tion, animals were randomly divided into two treatment groups: MK-80 1 treated and placebo treated. Alliabora tory personnel were blinded to the treatment regimen. Beginning at 5 min PR, animals received either MK-80 1 330 fLg/kg over 2 min followed by 73 fLg/kg/h for 10 h or the same volume of placebo (the vehicle for MK-80 1 con taining NaCI, benzylalcohol, and pH adjusted to 4.5 with HCI). MK-80 1 and placebo were obtained from Merck Sharp & Dohme Research Laboratories. This administra tion regimen of MK-80 1 was calculated to maintain a plasma level of 40 ng/ml. (In pilot studies the following pharmacokinetic data for MK-80 1 were determined in three normal cats: elimination rate constant = 0.003627; equilibrium volume of distribution = 8,333 mllkg; clear ance = 30 mllmin; elimination half-life = 19 1 min; dis tribution rate constant = 0.126; central volume of distri bution = 3,378 mllkg.)
Animals were maintained in an intensive care setting until 24-30 h PRo Controlled ventilation was continued with muscle paralysis provided by pancuronium. To min imize the stress of immobilization, midazolam 0.5 mg/kg bolus i. V. followed by 0.5 mg/kg/h was started at 1 h PR, by which time all animals had regained some EEG activ ity. The inspired gas mixture was changed to 40% Oz in nitrogen at 3 h PRo All animals received 5 cm HzO PEEP, which was increased up to 10 cm HzO as needed to main tain PaoZ at >100 mm Hg. Monitoring of MABP, RAP, end-tidal CO2, ECG, and EEG and intermittent analysis of arterial blood gases and electrolytes were continued during the intensive care period.
The MABP was maintained between 90 and 110 mm Hg until the time of arterial decannulation. Hypotension (MABP < 90 mm Hg) was treated by incremental admin istration of lactated Ringer's solution (total not to exceed 30 ml) and, if needed, infusion of norepinephrine (NA). Hypertension (MABP > 110 mm Hg) was treated by in fusion of trimethaphan (TMP). Metabolic acidosis was corrected by administration of additional bicarbonate (1-mEq increments). Respiratory acidosis and alkalosis were treated by adjustment of respiratory rate. The main tenance fluid was changed to 5% dextrose in 0.45% NaCI at 6 h PRo Animals were turned and the trachea was suc tioned every 4 h. Cefazolin 15 mg/kg was administered intramuscularly at the end of surgery and every 12 h (until 48 h PR).
At 20 h PR, the infusion of pancuronium and midazo lam was discontinued. After spontaneous muscle activity was observed, neostigmine 60 fLg/kg and atropine 40 I1g/kg were administered intravenously to reverse resid ual neuromuscular blockade and avoid bradycardia, re spectively. The trachea was extubated after P aCoZ was maintained below 45 mm Hg during spontaneous respira tion. The arterial and RA cannulas were removed (1-1.5% halothane in Oz by mask as needed). If animals did not regain spontaneous respiration, mechanical ventilation was continued for the next 6 h without muscle paralysis or sedation, and repeated trials of spontaneous ventila tion were made. If animals still did not regain spontane ous respiration, they were excluded from further study. Extubated animals were placed in a Plexiglas cage with ambient temperature maintained at 25°C. Oxygen, 5 LI min, was supplied until 2-3 days PRo An infusion of 5% dextrose in 0.45% NaCI was continued until 48 h PRo Thereafter, animals were fed strained baby food per os or via gastric tube as indicated. If needed, maintenance flu ids (40-60 mllkg/day) were injected subcutaneously.
Arterial blood gases were measured PR at 4-5 min (prior to MK-80 1 or placebo administration), 7 min, and every 15 min until 1 h, every hour until 6 h, and every 2 h until 24 h (or the time of removal of cannulas). Hemat ocrit and plasma glucose were examined PR at 4-5 min, 7 min, 1 h, and then every 4 h. Plasma electrolytes were analyzed PR at 4-5 min, 7 min, and 1, 4, 12, and 24 h. Plasma MK-80 1 levels were determined in seven treated cats at 8 h and 4 and 7 days PR (analysis performed by Merck Sharp & Dohme Research Laboratories). After the 7-day neurologic evaluation, animals were anesthetized with pentobarbital 30 mg/kg i.p. and perfusion-fixed with 10% buffered formalin following a saline rinse injected via the left ventricle. The brain was removed and fixed in 10% formalin solution for at least 2 weeks prior to histo pathologic examination.
Four sham-arrested animals were anesthetized, pre pared, and examined in exactly the same manner as the treatment groups, except that the heart was not arrested, neither MK-80 1 nor placebo was administered, and 0.5-1.5% halothane was continued from induction of an esthesia until 24 h "PR" to supplement the sedation pro duced by midazolam.
Neurological and neuropathological examinations
Neurological examination was performed at 2, 4, and 7 days PR by two observers blinded to the treatment groups. The animals were graded using a modification of the neurologic deficit score (NDS) described by Todd et al. (1982) (Table 1) , according to their level of conscious ness, respiratory pattern, cranial nerve function, muscle tone, motor responses to noxious stimuli, behavioral re actions, stance, and gait. A score of 0 indicates a normal animal, and a score of 100 indicates brain death. For sta tistical analysis, a mean of the scores determined by the two independent observers was calculated, and the mean value used as the NDS for each animal.
Histopathologic evaluation was performed by two ob servers who were blinded to treatment group and neuro logic score. Coronal sections of the left cerebral hemi sphere were histologically examined at three sites: (a) frontal cortex at the level of the anterior basal ganglia, (b) hippocampus at the level of the lateral geniculate nucleus, and (c) occipital cortex 4-5 mm anterior to the occipital pole. A midsagittal section of the cerebellum and a hori zontal section of the left cerebellar hemisphere were also examined. All tissues were dehydrated in a graded series of alcohols, cleared in xylene, and embedded in paraffi n. Sections were cut at a thickness of 6 fLm and stained with hematoxylin and eosin. Ischemic neurons were identified by the presence of shrunken, eosinophilic cytoplasm and homogeneous, pyknotic, or fragmented nuclei. Histologic sections were graded on a scale of 0-3 according to the fr equency of ischemic neurons in defined regions of each section. For the frontal and occipital cortex, 0 = normal, 1. E. FLEISCHER ET AL. from each region for a maximal neuropathologic score (NPS) of 12. The NPS was taken as the mean of the individual scores determined by each observer. Addi tional quantitative evaluation of the number of viable neu rons in the CAl and CA3 regions of the hippocampus was performed in the following manner. Cells were counted from photomicrographs of fields 900 ILm wide from the central portions of the CAl and CA3 regions (at a magni fication of 400x). Within each field, all pyramidal cells with a distinct nucleus within the plane of focus were counted. Hippocampal granule cells were not included in the quantitative analysis. All fields were counted by four observers (J.C.D., J.E.F., M.R.O., and M.H.Z.) blinded to treatment group and neurologic outcome. A mean cell count for each CAl and CA3 region was taken as the average of the four individual cell counts. Cell counts for CAl and CA3 regions were compared between MK-801-treated, placebo-treated, and sham-treated animals.
Predetermined exclusions
Animals were excluded from data analysis if any of the following conditions occurred: prearrest plasma glucose J Cereb Blood Flow Metab, Vol. 9, No.6, 1989 of > 180 mg/dl; any spontaneous heartbeat > 1 min into the arrest period; CPR duration of >4 min; P aOZ of <70 mm Hg and/or PaCOZ of >50 mm Hg for >30 min; MABP of <70 or > 130 mm Hg for >60 min or <50 mm Hg at any point; or evidence for a noncerebral cause of death (i.e., pulmonary edema, pneumonia, cardiac failure, etc.).
Statistics
Comparisons of physiologic and CA/CA3 quantitative data between the treatment groups were carried out with unpaired t tests. All data are presented as means ± SD. The Mann-Whitney rank sum test was used to identify intergroup differences in NDS at 2, 4, and 7 days PR and NPS. Mean NDS ± SD at 2, 4, and 7 days PR is also reported. Correlations between neurologic and pathologic scores were evaluated by Spearman's rank sum coeffi cient. Differences associated with critical values indicat ing a p < 0.05 level of probability were considered sta tistically significant.
RESULTS
Exclusions and complications/deaths
Four animals were excluded prior to randomiza tion; one was omitted (no arrest performed) for an elevated prearrest plasma glucose level (> 180 mg! dl), and three others could not be resuscitated within 4 min. Of the 21 cats successfully resusci tated and treated with either MK-801 or placebo, 3 placebo-treated cats did not survive the 7-day ob servation period (NS). One animal was killed at 6 days PR with a diagnosis of severe pneumonia (P a02 < 50 mm Hg); another was unable to be weaned from mechanical ventilation 30 h PR; and one died at 40 h PR following successful extubation with an unknown cause of death. One MK-801-treated cat was excluded when neuropathologic examination revealed congenital hydrocephalus.
Group match
Seventeen animals were entered into data analy sis: nine MK-801-treated and eight placebo-treated cats. The MK-801-treated and placebo-treated groups were well matched for sex (eight males and one female versus seven males and one female).
The prearrest body weight was significantly lower in the MK-801 group than in the placebo group (2.1 ± 0. 2 vs. 2.4 ± 0. 3 kg, respectively). There were no differences between the two groups in time of halo thane anesthesia (119 ± 14 vs. 115 ± 8 min) or end-tidal halothane concentration (0. 58 ± 0.11 vs.
0. 67 ± 0. 09%) immediately prior to cardiac arrest.
Pulsatile arterial blood pressure disappeared instan taneously with the fibrillating current in all animals, and all cats had an isoelectric EEG 2 min after the start of VF. The resuscitation time (165 ± 41 s MK-801 vs. 155 ± 44 s placebo), number of DC shocks, and total dose of drugs used during CPR were not significantly different between groups. Table 2 summarizes changes of physiologic vari ables in MK-S01-and placebo-treated groups.
Physiologic variables
There were no significant differences in prearrest or PR physiologic variables between groups, except for a greater RAP in the placebo-treated animals at 12 h PR (3 ± 2 vs. 7 ± 3 mm Hg, respectively). In both groups, the mean plasma glucose increased PR and remained elevated until 24 h PR. There were no significant differences in the total doses of NA (0.16 ± 0.19 mg/kg MK-SOI and 0.05 ± 0.1 mg/kg pla cebo) or TMP (20 ± 10 mg/kg MK-SOI and IS ± 4 mg/kg placebo) administered.
Mean plasma MK-SOl level was 45.1 ± 6.2 ng/ml at S h PR and <0.2 ng/ml at 4 and 7 days PRo 
NDS and neuropathology
MK-SOI-treated animals had a significantly greater NDS rank 2 days PR (12.1 vS. 5.6; p = O.OOS) ( Fig. 1 ). There were no significant differ-ences in NDS rank at 4 (10.3 MK-SOI vS. 7.5 pla cebo) and 7 (9.6 MK-SOI vS. S.3 placebo) days PRo There was good correlation between NDS deter mined by the two independent examiners (r = 0.97).
Histological examination of representative sec
tions of the brain (as described above) showed vari able neuronal ischemic injury. This was graded as described in Methods (NPS). Additionally, some brains showed the presence of rod-shaped microglia in areas of injury, with occasional microglial nodule formation. In the more severely injured animals, there was focal laminar necrosis and/or cavitation with macrophage infiltration. In a few animals, se vere injury with cavitation was seen in the basal ganglia or thalamus. This information is not in cluded in the quantitative analysis. Neovasculariza tion was seen in some regions where there was se vere neuronal injury. NPS rank was not signifi cantly different between groups (9.9 MK-SOI vS. S.O placebo; Fig. 2) . Figure 3 displays the lack of any significant differences in NPS between groups for any of the four brain regions examined. Selective quantitative comparison of the CAl and CA3 re gions of the hippocampus failed to reveal any sig nificant differences in neuronal survival between groups or regions (Table 3) . Large standard devia tions were noted for CAl and CA3 regions in both ischemic groups. There was no significant correla tion between NDS and CAl or CA3 cell count.
However, there was a significant correlation in both groups between NDS rank (7 days PR) and NPS rank (p < 0.01). All sham-arrested animals had a normal NDS at 2, 4, and 7 days PR and no ischemic pathologic changes were noted. 
FIG. 1. Neurologic deficit scores (NOS) at 2, 4, and 7 days post resuscitation (PR) (0 = normal, 100 = brain death). At 2 days PR, NOS rank was significantly greater in the MK-80Hreated animals (*p = 0.008; Mann-Whitney). There were no differences between groups at either 4 or 7 days PR. The most striking factor these studies have in common, besides the obvious decreases in neuronal damage, is that all employed some form of focal or forebrain ischemia (i.e., incomplete cerebral isch- (100) There were no significant differences between regions or groups. Numbers in parentheses refer to the percentage of nor mal cells relative to sham animals. Values are presented as means ± SO. emia). [In the gerbil, despite bilateral carotid artery occlusion, there remains some degree of residual blood flow (Levy and Brierley, 1974; Osburne and Halsey, 1975; Crockard et al., 1980; Suzuki et al., 1983) . In the rat model of forebrain ischemia, as employed by Church et al. (1988) and Park et al. (1988a) , Kagstrom et al. (1983) have demonstrated that ischemic CBF is <5% of control, but not zero.] This is in contrast to the complete global cerebral ischemic model (i.e., no CBF) used in the current study. We are aware of two other studies that have examined the effects of MK-801 on ischemic injury following complete global ischemia. Perkins et al. The contrast between the results of these two groups of investigations (incomplete focal ischemia versus complete global ischemia) is superficially striking. The former have indicated that MK-801 has protective effects, while the latter have not.
DISCUSSION
However, the results of these two groups of studies may not be entirely inconsistent as there are rea sons for the differences. The pathophysiologies of incomplete focal ischemia and complete global isch emia are quite different. In complete global isch emia the EEG becomes isoelectric within seconds as there is no blood flow to the brain. In this cir cumstance, cerebral ATP concentration has been shown to decrease to 25% of preischemic values within 4 min (Michenfelder and Theye, 1970) . Ow ing to the nature of the insult, there is no possibility for collateral blood flow. In contrast, with incom plete focal cerebral ischemia, there is a central area of severe ischemia surrounded by areas of progres sively less ischemia (the ischemic penumbra) until normal brain is reached. The ischemic penumbra is generally thought of as an area where cells are po tentially viable depending upon the adequacy of blood flow from collateral circulation and the cere bral metabolic rate. The lower the metabolic rate, the longer cells receiving diminished blood flow will be able to survive. Following middle cerebral artery occlusion in the squirrel monkey, the rate of decline of ATP in the ischemic region decreased steadily over 3 h to 30% of normal (Michenfelder and Sundt, 1971 ). If the rate of decline of ATP in an ischemic region is used as an indicator of the severity of an ischemic episode, then it is obvious that complete global ischemia imposes a more severe insult than incomplete ischemia. Based on the results of the present study and the findings of the numerous studies noted above, it appears that MK-801 is more likely to provide neuronal protection when some degree of residual CBF is present (i.e., incomplete ischemia). Alternatively, with respect to global ischemia as employed in the current study, any neu ronal protection provided by MK-801 is over whelmed by the severity of the neuronal insult.
The distinction between the results of EAA an tagonist administration in focal and global ischemia is reminiscent of the pattern of efficacy of barbitu rates in cerebral protection. The parallel is likely to be entirely coincidental. The efficacy of barbitu rates may be the result of metabolic suppression with a possible contribution from favorable redistri bution of CBF as a result of vasoconstriction in normal brain. Neither of these mechanisms is likely J Cereb Blood Flow Metab. Vol. 9, No.6, 1989 to be relevant to MK-801. In contrast to the actions of the barbiturates, MK-801 has been shown to sig nificantly increase local cerebral glucose utilization in the limbic system of the normal rat brain (Mc Culloch, 1987; Nehls et aI., 1988) and significantly increase CB F in normal dogs (Perkins et aI., 1988b ).
In the current study it is appropriate to question if the lack of beneficial action with MK-801 is a result of "inadequate" quantities reaching specific loca tions in the brain, Previous work has suggested that a plasma MK-801 concentration of 40 ng/ml pro vides cerebral protection from ischemia (G. T.
Shearman, unpublished data). The ability of MK-801 to cross the blood-brain barrier has been dem onstrated both in normal rats (Hucker et aI., 1983) and by anticonvulsant actions (Clineschmidt et aI., 1982 ). In the current study, the increased NDS at 2 days PR in the MK-801-treated animals supports the notion that MK-801 did cross the blood-brain barrier. This is consistent with a previous report of significant anesthetic actions of MK-801 (Scheller et aI., 1988) . Even though MK-801 appears to cross the blood-brain barrier unimpaired post ischemia, it is possible that inhomogeneous CBF post ischemia (Ames et aI., 1968) to areas rich in NMDA receptors (i.e., cerebral cortex, striatum, and hippocampus) (Cotman et aI., 1987) is "inadequate."
The feline cardiac arrest model of complete cere bral ischemia and neurologic evaluation has been used previously in our laboratory. Todd et al. (1982) administered thiopental to cats following successful resuscitation from cardiac arrest and found no im provement in NDS in these cats. However, they did find that survival was improved in thiopental treated cats, possibly through an anticonvulsant ac tion of the drug. More recently, Tateishi et al. (1989) found that nimodipine had no beneficial ef fect on either NDS or NPS when administered after successful resuscitation from cardiac arrest. The findings of that study were complicated by signifi cant decreases in MABP in the nimodipine-treated group during the PR period. In a more recent, as yet unpublished study, we found that glucose adminis tration (15 mllkg of dextrose 5% in 0.45% normal saline) 15 min prior to a 14-min cardiac arrest re sulted in a significant difference in NDS rank at 7 days PR (9.3 glucose vs. 3.7 saline; p = 0.0061, n = 6/group). This is a convincing demonstration that the cat cardiac arrest model, as currently employed in our laboratory, is capable of revealing significant differences in NDS in small groups of subjects, when such differences would be anticipated to ex ist.
In summary, MK-801 improved neither NDS nor neuropathology in a clinically relevant model of car-diac arrest. There were no differences between treated and untreated groups in any measured phys iologic variable to account for the lack of efficacy of MK-801. However, it should be kept in mind that this study examined only a single situation with rig idly controlled variables (i.e., plasma level of MK-801, duration of MK-801 administration, duration of cerebral ischemia, etc.). Our findings in the very specific circumstances of the current study are con sistent with recent reports from other laboratories and lead us to propose that MK-801 is more effec tive at attenuating ischemic neuronal injury when some degree of residual blood flow is present.
